Plain-English translation of NCT07489534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing PD-1Ab21-BCMA CAR-T cell therapy for people with multiple myeloma (a blood cancer) who have kidney dysfunction. The medication works by taking your own immune cells, engineering them in the laboratory to fight myeloma cancer cells, and giving them back to you. Early results suggest this treatment may help both the cancer and kidney function improve.
Multiple myeloma patients with kidney problems typically have worse outcomes and fewer good treatment options than those with healthy kidneys. This medication has shown promise in early studies of helping both the cancer and kidney function improve in myeloma patients, so researchers want to study it more carefully as a consolidation therapy—a treatment given after initial cancer treatment to help keep the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You will receive the engineered immune cell therapy as an infusion, likely in an outpatient or inpatient setting depending on your hospital's protocol. The study will monitor your health closely with blood tests and imaging to track how well the cancer responds and whether your kidney function improves. You'll need to maintain close contact with the research team so they can watch for side effects and measure how you're doing over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China